JP7869816B2 - 間質性膀胱炎／膀胱痛症候群を処置する方法 - Google Patents

間質性膀胱炎／膀胱痛症候群を処置する方法

Info

Publication number
JP7869816B2
JP7869816B2 JP2023571825A JP2023571825A JP7869816B2 JP 7869816 B2 JP7869816 B2 JP 7869816B2 JP 2023571825 A JP2023571825 A JP 2023571825A JP 2023571825 A JP2023571825 A JP 2023571825A JP 7869816 B2 JP7869816 B2 JP 7869816B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
formula
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023571825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518804A (ja
JP2024518804A5 (enExample
Inventor
ホワイトサイド，ガース
ハリス，ステファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Publication of JP2024518804A publication Critical patent/JP2024518804A/ja
Publication of JP2024518804A5 publication Critical patent/JP2024518804A5/ja
Application granted granted Critical
Publication of JP7869816B2 publication Critical patent/JP7869816B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023571825A 2021-05-21 2022-05-20 間質性膀胱炎／膀胱痛症候群を処置する方法 Active JP7869816B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163191536P 2021-05-21 2021-05-21
US63/191,536 2021-05-21
PCT/US2022/030400 WO2022246298A1 (en) 2021-05-21 2022-05-20 Methods of treating interstitial cystitis/bladder pain syndrome

Publications (3)

Publication Number Publication Date
JP2024518804A JP2024518804A (ja) 2024-05-02
JP2024518804A5 JP2024518804A5 (enExample) 2025-05-16
JP7869816B2 true JP7869816B2 (ja) 2026-06-03

Family

ID=84140895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571825A Active JP7869816B2 (ja) 2021-05-21 2022-05-20 間質性膀胱炎／膀胱痛症候群を処置する方法

Country Status (11)

Country Link
US (1) US20240269133A1 (enExample)
EP (1) EP4340837A4 (enExample)
JP (1) JP7869816B2 (enExample)
KR (1) KR20240012516A (enExample)
CN (1) CN117750958A (enExample)
AU (1) AU2022276010A1 (enExample)
BR (1) BR112023023702A2 (enExample)
CA (1) CA3219412A1 (enExample)
IL (1) IL308315A (enExample)
MX (1) MX2023013514A (enExample)
WO (1) WO2022246298A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119421705A (zh) * 2022-06-24 2025-02-11 普渡制药公司 治疗或预防膀胱过度活动综合征的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526712A (ja) 2004-12-31 2008-07-24 ブラネ ディスカヴァリー ソシエタ ア レスポンサビリタ リミタータ Ｏｒｌ−１受容体用の置換されたインドールリガンド
JP2008543826A (ja) 2005-06-17 2008-12-04 ファイザー株式会社 ＯＲＬ１−受容体アンタゴニストとしてのα−（アリール−またはヘテロアリール−メチル）−β−ピペリジノプロパン酸化合物
JP2011528707A (ja) 2008-07-21 2011-11-24 パーデュー、ファーマ、リミテッド、パートナーシップ 置換キノキサリンタイプ架橋ピペリジン化合物とその使用
JP2021511338A (ja) 2018-01-24 2021-05-06 パーデュー、ファーマ、リミテッド、パートナーシップ 睡眠障害の治療及び予防

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6572891B1 (en) 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
JP4739217B2 (ja) 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
WO2005117862A1 (en) * 2004-06-03 2005-12-15 Pfizer Limited, Treatment of urinary conditions including incontinence
CA2664315C (en) 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
EP2254556A2 (en) 2008-03-11 2010-12-01 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
US9040533B2 (en) * 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
EP3917621A1 (en) 2019-01-31 2021-12-08 Purdue Pharma LP Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526712A (ja) 2004-12-31 2008-07-24 ブラネ ディスカヴァリー ソシエタ ア レスポンサビリタ リミタータ Ｏｒｌ−１受容体用の置換されたインドールリガンド
JP2008543826A (ja) 2005-06-17 2008-12-04 ファイザー株式会社 ＯＲＬ１−受容体アンタゴニストとしてのα−（アリール−またはヘテロアリール−メチル）−β−ピペリジノプロパン酸化合物
JP2011528707A (ja) 2008-07-21 2011-11-24 パーデュー、ファーマ、リミテッド、パートナーシップ 置換キノキサリンタイプ架橋ピペリジン化合物とその使用
JP2021511338A (ja) 2018-01-24 2021-05-06 パーデュー、ファーマ、リミテッド、パートナーシップ 睡眠障害の治療及び予防

Also Published As

Publication number Publication date
JP2024518804A (ja) 2024-05-02
EP4340837A1 (en) 2024-03-27
WO2022246298A1 (en) 2022-11-24
MX2023013514A (es) 2024-04-02
KR20240012516A (ko) 2024-01-29
AU2022276010A1 (en) 2024-01-18
BR112023023702A2 (pt) 2024-01-30
CA3219412A1 (en) 2022-11-24
EP4340837A4 (en) 2025-04-09
US20240269133A1 (en) 2024-08-15
CN117750958A (zh) 2024-03-22
IL308315A (en) 2024-01-01

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250508

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260423

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260522

R150 Certificate of patent or registration of utility model

Ref document number: 7869816

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150